The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. Targeted treatment options for the HR-positive, HER2-negative segment have expanded in the United States following the market entries of Pfizer’s Ibrance (2015) and Novartis’s Kisqali (2017). This study shines a spotlight on the current treatment dynamics for HR-positive, HER2-negative breast cancer and examines how the triple-negative breast cancer population is now managed.
- What are the key drivers and obstacles determining current prescribing patterns for Ibrance in HR-positive/HER2-negative metastatic breast cancer?
- What is the uptake of recently approved Kisqali in newly diagnosed HR-positive/HER2-negative metastatic breast cancer? What is surveyed oncologists’ perception of Kisqali versus Ibrance?
- In the absence of any approved targeted therapy for triple-negative breast cancer, what is the patient share of key chemotherapeutic agents and regimens prescribed to newly diagnosed patients?
- What is the most-frequently prescribed sequence of treatment for HR-positive/HER2-negative metastatic breast cancer?
Key drugs covered: